Stage C hepatocellular carcinoma is typically managed with which approach?

Prepare for Liver Disease and Tumors Test with tailored flashcards and questions. Get detailed explanations and improve your knowledge. Ace the medical student exam!

Multiple Choice

Stage C hepatocellular carcinoma is typically managed with which approach?

Stage C hepatocellular carcinoma is advanced disease, usually with vascular invasion or spread beyond the liver. When cancer has moved beyond a localized area, a systemic treatment that can reach cancer cells throughout the body is needed, not just the liver. Systemic therapy—such as multikinase inhibitors or immunotherapy combinations—has the goal of slowing progression and extending survival in this setting. Resection is typically reserved for early-stage disease with limited tumor burden and good liver function, where the tumor is confined to the liver. TACE is a liver-directed treatment best used in intermediate-stage disease without vascular invasion, because vascular invasion or multifocal disease in Stage C makes locoregional therapy less effective and riskier. Palliative care is important for symptom management but does not address the systemic nature of Stage C disease.

Stage C hepatocellular carcinoma is advanced disease, usually with vascular invasion or spread beyond the liver. When cancer has moved beyond a localized area, a systemic treatment that can reach cancer cells throughout the body is needed, not just the liver. Systemic therapy—such as multikinase inhibitors or immunotherapy combinations—has the goal of slowing progression and extending survival in this setting.

Resection is typically reserved for early-stage disease with limited tumor burden and good liver function, where the tumor is confined to the liver. TACE is a liver-directed treatment best used in intermediate-stage disease without vascular invasion, because vascular invasion or multifocal disease in Stage C makes locoregional therapy less effective and riskier. Palliative care is important for symptom management but does not address the systemic nature of Stage C disease.

More practice questions